176 related articles for article (PubMed ID: 32939795)
1. De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: clinicopathological correlation.
Bui AN; Hirner J; Singer SB; Eberly-Puleo A; Larocca C; Lian CG; LeBoeuf NR
Clin Exp Dermatol; 2021 Mar; 46(2):328-337. PubMed ID: 32939795
[TBL] [Abstract][Full Text] [Related]
2. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
Marano AL; Clarke JM; Morse MA; Shah A; Barrow W; Selim MA; Hall RP; Cardones AR
Br J Dermatol; 2019 Sep; 181(3):580-583. PubMed ID: 30244487
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced subacute cutaneous lupus erythematosus associated with abatacept.
Figueredo Zamora E; Callen JP; Schadt CR
Lupus; 2021 Apr; 30(4):661-663. PubMed ID: 33349110
[TBL] [Abstract][Full Text] [Related]
4. Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab.
Kosche C; Owen JL; Choi JN
Dermatol Online J; 2019 Oct; 25(10):. PubMed ID: 31735010
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart.
Marzano AV; Lazzari R; Polloni I; Crosti C; Fabbri P; Cugno M
Br J Dermatol; 2011 Aug; 165(2):335-41. PubMed ID: 21564069
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of drug-induced subacute cutaneous lupus erythematosus.
Lowe GC; Henderson CL; Grau RH; Hansen CB; Sontheimer RD
Br J Dermatol; 2011 Mar; 164(3):465-72. PubMed ID: 21039412
[TBL] [Abstract][Full Text] [Related]
7. [Subacute cutaneous lupus erythematosus induced by terbinafine].
Amitay-Layish I; Feuerman H; David M
Harefuah; 2006 Jul; 145(7):480-2, 552. PubMed ID: 16900733
[TBL] [Abstract][Full Text] [Related]
8. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation.
Sontheimer RD; Henderson CL; Grau RH
Arch Dermatol Res; 2009 Jan; 301(1):65-70. PubMed ID: 18797894
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
Coleman E; Ko C; Dai F; Tomayko MM; Kluger H; Leventhal JS
J Am Acad Dermatol; 2019 Apr; 80(4):990-997. PubMed ID: 30399387
[TBL] [Abstract][Full Text] [Related]
10. Lichenoid and subacute cutaneous lupus erythematosus-like dermatitis associated with antihistamine therapy.
Crowson AN; Magro CM
J Cutan Pathol; 1999 Feb; 26(2):95-9. PubMed ID: 10082400
[TBL] [Abstract][Full Text] [Related]
11. Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy.
Andersson NW; Zachariae C; Simonsen AB
Eur J Cancer; 2021 Mar; 145():168-170. PubMed ID: 33486439
[No Abstract] [Full Text] [Related]
12. Subacute cutaneous lupus erythematosus in the course of rheumatoid arthritis: a relationship with TNF-α antagonists and rituximab therapy?
Lis-Święty A; Brzezińska-Wcisło L; Widuchowska M; Kucharz E
Immunopharmacol Immunotoxicol; 2013 Jun; 35(3):443-6. PubMed ID: 23537059
[TBL] [Abstract][Full Text] [Related]
13. Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer.
Gambichler T; Doerler M; Scheel CH
Lupus; 2021 Mar; 30(3):531-533. PubMed ID: 33407044
[No Abstract] [Full Text] [Related]
14. Subacute cutaneous lupus erythematosus as a rare complication of disease-modifying therapy administration in multiple sclerosis: case report.
Xu K; Zhang M; Yang S; Yu G; Zheng P; Qin X; Feng J
BMC Neurol; 2023 Apr; 23(1):168. PubMed ID: 37101279
[TBL] [Abstract][Full Text] [Related]
15. Subacute cutaneous lupus erythematosus in childhood.
Amato L; Coronella G; Berti S; Moretti S; Fabbri P
Pediatr Dermatol; 2003; 20(1):31-4. PubMed ID: 12558843
[TBL] [Abstract][Full Text] [Related]
16. Subacute cutaneous lupus erythematosus.
David-Bajar KM
J Invest Dermatol; 1993 Jan; 100(1):2S-8S. PubMed ID: 8423385
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitors-related subacute cutaneous lupus erythematosus: Clinical characteristics, management, and outcome.
Deng Z; Guo A; Wu C; Wang C
J Cosmet Dermatol; 2022 Dec; 21(12):7202-7208. PubMed ID: 36214602
[TBL] [Abstract][Full Text] [Related]
18. Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review.
Zitouni NB; Arnault JP; Dadban A; Attencourt C; Lok CC; Chaby G
Melanoma Res; 2019 Apr; 29(2):212-215. PubMed ID: 30489484
[TBL] [Abstract][Full Text] [Related]
19. Poikilodermatous subacute cutaneous lupus erythematosus.
Marzano AV; Facchetti M; Alessi E
Dermatology; 2003; 207(3):285-90. PubMed ID: 14571071
[TBL] [Abstract][Full Text] [Related]
20. Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab - a case report.
Fietz S; Fröhlich A; Mauch C; de Vos-Hillebrand L; Fetter T; Landsberg J; Hoffmann F; Sirokay J
Front Immunol; 2023; 14():1324231. PubMed ID: 38143738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
